Literature DB >> 27119551

HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.

Tatiana V Kudryashova1, Dmitry A Goncharov1, Andressa Pena1, Neil Kelly2, Rebecca Vanderpool1, Jeff Baust1, Ahasanul Kobir1, William Shufesky3, Ana L Mora1,2, Adrian E Morelli3, Jing Zhao2, Kaori Ihida-Stansbury4,5, Baojun Chang1,2, Horace DeLisser5,6, Rubin M Tuder7, Steven M Kawut5,8, Herman H W Silljé9, Steven Shapiro2, Yutong Zhao1,2, Elena A Goncharova1,2.   

Abstract

RATIONALE: Enhanced proliferation and impaired apoptosis of pulmonary arterial vascular smooth muscle cells (PAVSMCs) are key pathophysiologic components of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH).
OBJECTIVES: To determine the role and therapeutic relevance of HIPPO signaling in PAVSMC proliferation/apoptosis imbalance in PAH.
METHODS: Primary distal PAVSMCs, lung tissue sections from unused donor (control) and idiopathic PAH lungs, and rat and mouse models of SU5416/hypoxia-induced pulmonary hypertension (PH) were used. Immunohistochemical, immunocytochemical, and immunoblot analyses and transfection, infection, DNA synthesis, apoptosis, migration, cell count, and protein activity assays were performed in this study.
MEASUREMENTS AND MAIN RESULTS: Immunohistochemical and immunoblot analyses demonstrated that the HIPPO central component large tumor suppressor 1 (LATS1) is inactivated in small remodeled pulmonary arteries (PAs) and distal PAVSMCs in idiopathic PAH. Molecular- and pharmacology-based analyses revealed that LATS1 inactivation and consequent up-regulation of its reciprocal effector Yes-associated protein (Yap) were required for activation of mammalian target of rapamycin (mTOR)-Akt, accumulation of HIF1α, Notch3 intracellular domain and β-catenin, deficiency of proapoptotic Bim, increased proliferation, and survival of human PAH PAVSMCs. LATS1 inactivation and up-regulation of Yap increased production and secretion of fibronectin that up-regulated integrin-linked kinase 1 (ILK1). ILK1 supported LATS1 inactivation, and its inhibition reactivated LATS1, down-regulated Yap, suppressed proliferation, and promoted apoptosis in PAH, but not control PAVSMCs. PAVSM in small remodeled PAs from rats and mice with SU5416/hypoxia-induced PH showed down-regulation of LATS1 and overexpression of ILK1. Treatment of mice with selective ILK inhibitor Cpd22 at Days 22-35 of SU5416/hypoxia exposure restored LATS1 signaling and reduced established pulmonary vascular remodeling and PH.
CONCLUSIONS: These data report inactivation of HIPPO/LATS1, self-supported via Yap-fibronectin-ILK1 signaling loop, as a novel mechanism of self-sustaining proliferation and apoptosis resistance of PAVSMCs in PAH and suggest a new potential target for therapeutic intervention.

Entities:  

Keywords:  HIPPO/LATS1; ILK; PAH; proliferation/apoptosis imbalance; vascular smooth muscle

Year:  2016        PMID: 27119551      PMCID: PMC5074651          DOI: 10.1164/rccm.201510-2003OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  49 in total

Review 1.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

2.  Towards a proteome-scale map of the human protein-protein interaction network.

Authors:  Jean-François Rual; Kavitha Venkatesan; Tong Hao; Tomoko Hirozane-Kishikawa; Amélie Dricot; Ning Li; Gabriel F Berriz; Francis D Gibbons; Matija Dreze; Nono Ayivi-Guedehoussou; Niels Klitgord; Christophe Simon; Mike Boxem; Stuart Milstein; Jennifer Rosenberg; Debra S Goldberg; Lan V Zhang; Sharyl L Wong; Giovanni Franklin; Siming Li; Joanna S Albala; Janghoo Lim; Carlene Fraughton; Estelle Llamosas; Sebiha Cevik; Camille Bex; Philippe Lamesch; Robert S Sikorski; Jean Vandenhaute; Huda Y Zoghbi; Alex Smolyar; Stephanie Bosak; Reynaldo Sequerra; Lynn Doucette-Stamm; Michael E Cusick; David E Hill; Frederick P Roth; Marc Vidal
Journal:  Nature       Date:  2005-09-28       Impact factor: 49.962

3.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

4.  Capturing the mammalian Hippo: elucidating its role in cancer.

Authors:  Miki Nishio; Kohei Otsubo; Tomohiko Maehama; Koshi Mimori; Akira Suzuki
Journal:  Cancer Sci       Date:  2013-08-07       Impact factor: 6.716

5.  Vascular smooth muscle cell phenotypes in primary pulmonary hypertension.

Authors:  Y Mitani; M Ueda; R Komatsu; K Maruyama; R Nagai; M Matsumura; M Sakurai
Journal:  Eur Respir J       Date:  2001-02       Impact factor: 16.671

6.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

Authors:  Yi Liu-Chittenden; Bo Huang; Joong Sup Shim; Qian Chen; Se-Jin Lee; Robert A Anders; Jun O Liu; Duojia Pan
Journal:  Genes Dev       Date:  2012-06-07       Impact factor: 11.361

Review 7.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

8.  Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.

Authors:  Dmitry A Goncharov; Tatiana V Kudryashova; Houman Ziai; Kaori Ihida-Stansbury; Horace DeLisser; Vera P Krymskaya; Rubin M Tuder; Steven M Kawut; Elena A Goncharova
Journal:  Circulation       Date:  2013-11-22       Impact factor: 29.690

9.  Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase.

Authors:  Isabel Serrano; Paul C McDonald; Frances Lock; William J Muller; Shoukat Dedhar
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Notch3 signaling promotes the development of pulmonary arterial hypertension.

Authors:  Xiaodong Li; Xiaoxue Zhang; Robin Leathers; Ayako Makino; Chengqun Huang; Pouria Parsa; Jesus Macias; Jason X-J Yuan; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  Nat Med       Date:  2009-10-25       Impact factor: 53.440

View more
  40 in total

1.  Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-06-22       Impact factor: 5.464

Review 2.  Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.

Authors:  Soni Savai Pullamsetti; Rajkumar Savai; Werner Seeger; Elena A Goncharova
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

3.  Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.

Authors:  Hyung J Chun; Sébastien Bonnet; Stephen Y Chan
Journal:  Am J Respir Crit Care Med       Date:  2017-01-15       Impact factor: 21.405

4.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

Review 5.  The role of Hippo/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease.

Authors:  Jinlong He; Qiankun Bao; Meng Yan; Jing Liang; Yi Zhu; Chunjiong Wang; Ding Ai
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

Review 6.  Tissue-informed engineering strategies for modeling human pulmonary diseases.

Authors:  Kolene E Bailey; Michael L Floren; Tyler J D'Ovidio; Steven R Lammers; Kurt R Stenmark; Chelsea M Magin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-21       Impact factor: 5.464

7.  Effect of antenatal tetramethylpyrazine on lung development and YAP expression in rat model of experimental congenital diaphragmatic hernia.

Authors:  Junzuo Liao; Wenying Liu; Libin Zhang; Qin Li; Fang Hou; Pingjin Zou
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

8.  Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension.

Authors:  Thomas Bertero; William M Oldham; Katherine A Cottrill; Sabrina Pisano; Rebecca R Vanderpool; Qiujun Yu; Jingsi Zhao; Yiyin Tai; Ying Tang; Ying-Yi Zhang; Sofiya Rehman; Masataka Sugahara; Zhi Qi; John Gorcsan; Sara O Vargas; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Kathleen J Haley; Aaron B Waxman; Victoria N Parikh; Teresa De Marco; Priscilla Y Hsue; Alison Morris; Marc A Simon; Karen A Norris; Cedric Gaggioli; Joseph Loscalzo; Joshua Fessel; Stephen Y Chan
Journal:  J Clin Invest       Date:  2016-08-22       Impact factor: 14.808

Review 9.  Emerging therapeutics in pulmonary hypertension.

Authors:  Matthew K Hensley; Andrea Levine; Mark T Gladwin; Yen-Chun Lai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-01       Impact factor: 5.464

Review 10.  Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.